Dossier assessment

Teplizumab (type 1 diabetes mellitus, >= 8 years) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A26-11
Last updated

Report documents

  1. Extract of dossier assessment

    Teplizumab (type 1 diabetes mellitus, >= 8 years) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 646 kB, EN, not accessible
    DOI-Link
    https://doi.org/10.60584/A26-11_en
  2. Dossier assessment

    Teplizumab (type 1 diabetes mellitus, >= 8 years) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 877 kB, DE, not accessible
    DOI-Link
    https://doi.org/10.60584/A26-11

Drug assessment at a glance

  1. Drug assessment at a glance

    Teplizumab (type 1 diabetes mellitus, >= 8 years) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 246 kB, EN, not accessible

Dossier assessment

Indication:

Adult and paediatric patients 8 years of age and older with stage 2 type 1 diabetes mellitus, to delay the onset of stage 3

Result of dossier assessment:
  • For patients with a family history: added benefit not proven (based on the results of the relevant study)
  • For patients without a family history: added benefit not proven (no relevant study)

Additional information

Federal Joint Committee (G-BA)

06-08-2026 A G-BA decision was published.
G-BA documents on this decision

Project details

Project no.
A26-11
Commission
Commission awarded on 15.02.2026 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Digestion, metabolism and hormones
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A26-11_en

Connected Projects

  1. Addendum

    Teplizumab (type 1 diabetes mellitus, stage 2, >= 8 years) – Addendum to Project A26-11

    Project no.
    A26-73
    Last updated

    Status: Commission completed

  2. Addendum

    Teplizumab (type 1 diabetes mellitus, stage 2, >= 8 years) – Second addendum to Project A26-11

    Project no.
    G26-17
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form